Fungal infections explode immune cells and shape-shift to defeat human immunity

Publicly released:
Australia; International; VIC; QLD; ACT
TopMicrobialStock via Getty Images
TopMicrobialStock via Getty Images

Scientists from Monash University have discovered how the world’s deadliest fungi explode immune cells and shape-shift to defeat the human immune system, providing new avenues for treatments and drug discovery. Candida auris and Candida albicans are microscopic fungi that cause life-threatening human infections, killing almost a million people globally every year. The World Health Organization lists both species among the top four most concerning fungal pathogens in existence.

News release

From: Monash University

Scientists from Monash University have discovered how the world’s deadliest fungi explode immune cells and shape-shift to defeat the human immune system, providing new avenues for treatments and drug discovery.

Candida auris and Candida albicans are microscopic fungi that cause life-threatening human infections, killing almost a million people globally every year.

The World Health Organization lists both species among the top four most concerning fungal pathogens in existence, and while relatively uncommon in Australia, growing outbreaks in Europe and the United States have been responsible for forcing restriction and even closure of Intensive Care Units.

New Monash University research, published in Nature Communications and Nature Microbiology, opens the door for therapeutic treatments and antifungal drug discovery by identifying the nutrients the fungi and immune cells use to battle each other.

The Nature Communications study identified a critical, naturally occurring amino acid called alanine that reverses the process these fungi use to defeat the immune system.

When an immune cell ‘swallows’ a fungal microbe to destroy it, the fungus fights back from the inside, triggering the host protein Ninjurin (NINJ1) to form large pores, causing the immune cell to explode and release the fungal cells to spread the infection.

By supplying a higher dosage of alanine, researchers successfully blocked the protein, preventing the immune cells from bursting, thereby containing the fungal cells.

First author Dr Harshini Weerasinghe, Research Fellow at the Monash Biomedicine Discovery Institute, said keeping the pathogen securely trapped in a cellular bottleneck would ensure it could be contained and targeted more effectively.

“This gives us an option to treat the patient by strengthening their immune system, potentially in conjunction with antifungals that can eradicate it,” Dr Weerasinghe said.

“Fungi are remarkably similar to humans at the cell biology level, so often the drugs that harm the fungi also harm the patient. This is a real problem for finding new effective treatments.

“Finding a new way to contain the infection, literally inside the immune cells, would be a game-changer.”

The Nature Microbiology study discovered the shape-shifting ability of the mysterious Candida auris, which can adapt itself to stick to human tissue and remain invisible to human immune cells in different parts of the body.

In the bloodstream, it consumes glucose and stays in a small and round shape that immune cells do not recognise as a threat. When Candida auris find different sugars that are normally present on skin it becomes long and sticky, allowing it to attach and persist under these conditions.

First author Irma Tedja, PhD Candidate at the Monash Biomedicine Discovery Institute, said this understanding is critical to finding treatment options.

“Because it is so new, little was known about how this fungi thrives on human skin and evades detection,” Tedja said.

“Our discovery shows Candida auris acts as a clever environmental sensor, monitoring the types of sugars available in human tissue and changing its cell shape and properties to stick to skin while evading immune systems in conditions found in the bloodstream.

“Understanding this nutritional trigger opens the door to finding ways in which we could prevent the fungus from hiding or anchoring to the body.”

Senior author on both papers, Professor Ana Traven from the Monash Biomedicine Discovery Institute, said drastic environmental and economic shifts in recent years have made the work of the world’s few fungal experts all the more important.

"Fungi cause deadly infections and are being supported by changing climate conditions,” Professor Traven said.

“We have few traditional antifungals to control these infections, and pharmaceutical companies have largely pulled out of developing new antibiotics and antifungal therapies because it isn't economically beneficial.

“So, we need to think laterally. In addition to finding new ways to poison the fungus, we are also looking at how we could nutritionally manipulate the patient's body to give their immune system the energy and tools to fight back."

Read the research paper in Nature Communications: https://doi.org/10.1038/s41467-026-74195-6

This research is a collaboration between Monash University, the Walter and Eliza Hall Institute of Medical Research, the Hudson Institute of Medical Research, The University of Queensland, the Australian National University and The Hans Knöll Institute (Germany).

Read the research paper in Nature Microbiology: https://doi.org/10.1038/s41564-026-02454-9

This research is a collaboration between Monash University and Purdue University (United States). It benefited from cross-disciplinary and international collaborations with Professor Traude Beilharz at Monash University and Associate Professor Shankar Thangamani at Purdue University.

Journal/
conference:
Nature Communications, Nature Microbiology
Research: Link to Paper 1 | Paper 2
Organisation/s: Monash University, The University of Queensland, Hudson Institute of Medical Research, The University of Melbourne, The Australian National University
Funder: Investigator grant 2033452 (A.T.), Investigator grant 2008692 (J.E.V.), Investigator 2009075 and Synergy 2009677 grants (K.S.), Ideas grant 2019765 (A.T., A.J.R.), Ideas grant APP2002520 (A.T.), Project grant APP158678 (A.T.), Ideas grant 2020757 (A.J.R., S.B.), Ideas grant APP1181089 (K.E.L.), the Australian Research Council: Future Fellowship FT190100733 (A.T.), Future Fellowship FT190100266 (K.E.L.), the German Research Foundation (Deutsche Forschungsgemeinschaft) (D.F.G.) within the Priority Program SPP2225 “Exit strategies of intracellular pathogens” (Project 446404928) (B.H.) and within the Cluster of Excellence ‘Balance of the Microverse’, under Germany’s Excellence Strategy, EXC 2051, Project ID 390713860 (B.H.). Grants from the Australian National Health and Medical Research Council (NHMRC) (Ideas Grant APP2002520 and Investigator Grant 2033452 to A.T.), the National Institutes of Health (NIH) (1R01AI177604 to S.T.), and Australian Research Council (ARC) Centre of Excellence Grant CE230100001 to M.J.M. and T.H.B. C.S. was supported by a fellowship from the Monash-Warwick Alliance Program in Emerging Superbug Threats.
Media Contact/s
Contact details are only visible to registered journalists.